TreatSMA

Remembering our angels who we have sadly lost

You will be aware on the 8th August we remember all those who we lost to SMA. Our angels who we continue to remember with love. As a type 1 father who lost my son Toby, it is not just one day, I remember him everyday.

So we have for families who have lost someone opened a small private Facebook page called Fallen Petals, it will be a moderated space as we want a little place where we can share our memories, love and thoughts for all the little angels who we miss so much. If you want to join this area please search for Treatsma Fallen Petals or follow the link below and we will let you in. Please do ensure you answer the membership questions so that we can accept your request.

With much love Joseph ❤️

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more